Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Leucid Bio Ltd.
DescriptionAutologous chimeric antigen receptor (CAR) T cells targeting eight of nine homo and heterodimers formed by the ErbB family
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase I
Standard IndicationHead and neck cancer
Indication DetailsTreat squamous cell cancer of the head and neck (SCCHN)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today